Can-Fite BioPharma Ltd. (CANF) Stock Score, Valuation & Financial Research
Can-Fite BioPharma Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for CANF
Can-Fite BioPharma Ltd. currently has a Wall Street Score of 22/100. The stored market price is $2.24. Its financial score is 24/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Can-Fite BioPharma Ltd. does
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations;
CANF financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $2.24
- Market capitalization:
- $2.9M
- Revenue:
- $405K
- Net income:
- $-9.8M
- Free cash flow:
- $-9.0M
- Cash:
- $5.5M
- Total debt:
- $71K
- EPS:
- -0.02
- Financial score:
- 24/100
- Valuation score:
- 0/100
- Revenue score:
- 1/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-9.0M, showing cash burn in the current stored period.
- The balance sheet shows $5.5M of cash versus $71K of total debt, leaving more cash than debt.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research CANF
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.